Tardio Jason 4

What Happened

• Jason Tardio, President and Chief Operating Officer of IMMUNIC, Inc. (IMUX), was granted a derivative award reported as options to purchase 253,000 shares on June 29, 2026. The filing lists an acquisition price of $0.00 and shows this as a grant/award (code A); no cash was exchanged on the reported grant.

Key Details

• Transaction date: 2026-06-29 (filing dated same day).
• Grant size: options covering 253,000 shares; exercise/price reported in the filing as $0.00.
• Shares owned after transaction: not specified in the information provided.
• Footnote F1: Grant represents options conditionally approved by the Board and subject to amendment of the 2019 Omnibus Equity Incentive Plan; shareholder approval of that amendment was obtained at the company’s June 29, 2026 annual meeting.
• Footnote F2: Vesting: 25% vests on April 2, 2027, then the remaining 75% vests in equal monthly increments over the following 36 months.
• Timeliness: Filing and transaction date the same day; no late filing flag was indicated.

Context

• This was an options/award grant (compensation), not an open-market purchase or sale — it does not represent an immediate change in market exposure unless and until the options are exercised and shares acquired or sold. Grants to executives are common as part of incentive compensation; vesting schedule means value is realized over time and depends on future stock performance and any exercise terms.